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Abstract
Background: Diets high in cereal-fiber (HCF) have been shown to improve whole-body insulin sensitivity. In search
for potential mechanisms we hypothesized that a supplemented HCF-diet influences the composition of the
human gut microbiota and/or biomarkers of colonic carbohydrate fermentation.
Methods: We performed a randomized controlled 18-week intervention in group-matched overweight participants.
Fecal samples of 69 participants receiving isoenergetic HCF (cereal-fiber 43 g/day), or control (cereal-fiber 14 g/
day), or high-protein (HP, 28% of energy-intake, cereal-fiber 14 g/day), or moderately high cereal fiber/protein diets
(MIX; protein 23% of energy-intake, cereal-fiber 26 g/day) with comparable fat contents were investigated for diet-
induced changes of dominant groups of the gut microbiota, and of fecal short-chain fatty-acids (SCFA) including
several of their proposed targets, after 0, 6, and 18-weeks of dietary intervention. In vitro fermentation of the cereal
fiber extracts as used in the HCF and MIX diets was analyzed using gas chromatography. Diet-induced effects on
whole-body insulin-sensitivity were measured using euglycaemic-hyperinsulinemic clamps and re-calculated in the
here investigated subset of n = 69 participants that provided sufficient fecal samples on all study days.
Results: Gut microbiota groups and biomarkers of colonic fermentation were comparable between groups at
baseline (week 0). No diet-induced differences were detected between groups during this isoenergetic
intervention, neither in the full model nor in uncorrected subgroup-analyses. The cereal-fiber extract as used for
preparation of the supplements in the HCF and MIX groups did not support in vitro fermentation. Fecal acetate,
propionate, and butyrate concentrations remained unchanged, as well as potential targets of increased SCFA,
whereas valerate increased after 6-weeks in the HP-group only (p = 0.037). Insulin-sensitivity significantly increased
in the HCF-group from week-6 (baseline M-value 3.8 ± 0.4 vs 4.3 ± 0.4 mg·kg
-1·min
-1, p = 0.015; full model 0-18-
weeks, treatment-x-time interaction, p = 0.046).
Conclusions: Changes in the composition of the gut microbiota and/or markers of colonic carbohydrate
fermentation did not contribute explaining the observed early onset and significant improvement of whole-body
insulin sensitivity with the here investigated HCF-diet.
Trial registration: This trial was registered at http://www.clinicaltrials.gov as NCT00579657
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It is generally assumed that the beneficial effects of insolu-
ble cereal fiber arise from chronic intake and its subsequent
fermentation in the colon [1-4]. In prospective cohort
studies cereal fiber intake is associated with improved insu-
lin sensitivity [5,6] and reduced risk for developing Type 2
Diabetes, after correction for confounders [7,8]. In rando-
mized controlled interventions several [9-12], but not all
[13] previous studies show improved whole-body insulin
sensitivity with HCF diets, with the effects likely being dose
dependent [12]. However, most cereal fibers are fermented
only moderately [14]. Since reduced risk of diabetes is most
consistently observed with a high intake of cereal fibers, as
opposed to more readily fermentable sources of fiber such
as fruit and vegetables [7,8], it is not clear whether changes
in the gut microbiota and/or colonic fermentation are
indeed key factors involved in conveying improved insulin
sensitivity with a HCF intake.
In rodent models highly fermentable fibers such as oli-
gofructose and resistant starch have been shown to lead to
short chain fatty acid (SCFA)-induced up-regulation of
pro-glucagon mRNA, resulting in increased glucagon like
peptide-1 (GLP-1) and other factors that are assumed to
have beneficial metabolic effects [15,16]. However, results
in human studies are controversial [17-20]: as an example,
exposure to highly fermentable resistant starch did not
result in any detectable changes in circulating GLP-1 con-
centrations, despite significant improvement of insulin
sensitivity [17,20]. Furthermore, it has been shown
recently that measurable changes of circulating GLP-1
concentrations due to a high intake of cereal fiber may
need as long as 9 months of continued ingestion in
humans [1].
No previous studies in humans are available that per-
formed parallel investigation of diet induced changes in
dominant groups of the human gut microbiota, markers
of colonic carbohydrate fermentation, and state of the art
measurement of insulin sensitivity. We have recently
shown that the here used isoenergetic HCF diet signifi-
cantly improves whole-body insulin sensitivity by 16%
from 6-weeks of dietary intervention [12]. We here inves-
tigated whether improved insulin sensitivity in response
to the HCF diet is associated with changes in markers of
colonic carbohydrate fermentation and/or in the compo-
sition of dominant groups of the human gut microbiota,
concepts that could further contribute explaining the
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participants had given their written informed consent.
Primary outcome measures were diet-induced changes
in whole-body and hepatic insulin sensitivity. Factors
that might contribute to explain altered insulin sensitiv-
ity were secondary outcomes that included the measure-
ment of markers of colonic carbohydrate fermentation
and dominant groups of the human gut microbiota
(Clinicaltrials.gov NCT00579657).
Effects of the diets on the primary outcomes and details
of the dietary intervention have been published [12]. In
brief, 111 overweight adults with features of the metabolic
syndrome were randomly assigned to one of four two-
phased, 18-weeks isoenergetic diets, by group-matching;
the percentages of energy derived from protein and carbo-
hydrates, and intake of cereal fiber per day were 17%/52%/
14 g (control); 17%/52%/43g (HCF); 28%/43%/13g (HP);
and 23%/44%/26g (MIX) after 6-weeks, and 17%/51%/15g
(control); 17%/51%/41g (HCF); 26%/45%/14g (HP); and
22%/46%/26g (MIX) after 18-weeks, according to 3-day
food protocols. Fat-intake was aimed to be 30% of energy
in all groups. Adherence was supported by intense dietary
advice and the provision of tailored dietary supplements
twice daily in all groups.
Out of the n = 111 participants that were randomised to
their respective diets, n = 84 participants fulfilled the all
inclusion criteria after 18-weeks of dietary intervention (i.
e. no relevant changes in body weight during this isoener-
getic intervention, no intake of drugs known to influence
insulin sensitivity, such as cortisone and antibiotics, and
no major problems with dietary adherance), as detailed
elsewhere [12]. Analyses in the present study were focused
on potential changes of markers of colonic carbohydrate
fermentation and dominant groups of the human gut
microbiota in the HCF group, which could contribute
explaining the observed HCF diet-induced improvement
of insulin sensitivity [12]. Sufficient fecal samples (cor-
rectly sampled fecal material on all 3 study days) were
available in n = 69 of these participants. All analyses were
performed in this subset, after 0, 6 and 18 weeks of dietary
intervention.
Subjects
Details have been published [12]. In brief: for eligibility
participants had to be 24 - 70 years of age and to be over-
weight (body-mass-index (BMI) >25 kg/m² (n = 45) or
obese (BMI > 30 kg/m², n = 66), with a waist circumfer-
ence > 80 cm in females and > 94 cm in males, and show
at least one more feature of the metabolic syndrome
according to IDF criteria [21]. Characteristic of glucose
metabolism (normal fasting glucose, impaired fasting glu-
cose and/or impaired glucose tolerance, according to oral
glucose tolerance tests) were comparable between
groups. Major exclusion criteria were pregnancy, dia-
betes, diseases of heart, liver, or kidneys, allergies includ-
ing food allergies, and metal implants. Further exclusion
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sical activity during the study, the intake of drugs known
to affect insulin sensitivity which included the intake of
antibiotics, and relevant problems with dietary adherence
[12].
Measurement of changes in dominant groups of the gut
microbiota
Fecal collection, fluorescence in situ hybridization (FISH)
and bacterial enumeration by flow cytometry were per-
formed essentially as described [22]. In brief, freshly
voided fecal samples were transported in air-tight plastic
boxes under anaerobic conditions (AnaeroGen, Oxoid)
a n ds t o r e da t4 ° C .T h e yw e r ep r o c e s s e dw i t h i n3h o u r s
after defecation by paraformaldehyde fixation as described
previously [22]. After fixation bacterial cells were washed
once with PBS, then resuspended in PBS and one volume
of ethanol was added. Samples were stored at -80°C until
analysis. For in situ hybridization, fixed bacterial cells were
washed once in 10× PBS and once in Tris-EDTA buffer
(100 mM Tris-HCl [pH 8.0], 50 mM EDTA). The follow-
ing lysozyme treatment for permeabilization and the
hybridization with the respective group-specific (Cy5
labelled) and all bacteria detecting EUB 338 (FITC
labelled) probes (additional file 1, Table S1) and stringency
washing procedures were described by Mueller et al [22].
Flow cytometry data acquisition was performed with a
FACS Calibur flow cytometer (Becton Dickinson) as
described previously [23] using the settings of Mueller et
al [22].
Cells belonging to a bacterial group or species were
enumerated with a group or species-specific probe as
the relative proportion of the cells detected with the
EUB 338 probe, which detects all bacteria. This propor-
tion was corrected by subtracting the background fluor-
escence obtained with the negative control probe
NONEUB 338.
Changes in gut microbiota were measured at 0, 6, and
18 weeks, for the following groups with the respective oli-
gonucleotide probe given in brackets: Clostridium coc-
coides - Eubacterium rectale cluster (Erec482), Roseburia
genus (Rrec584), Bacteroides-Prevotella (Bac303), Clostri-
dium leptum cluster (Clep866), Atopobium cluster
(Ato291), Bifidobacterium group (Bif164), and clostridial
cluster IX (Prop853). Lactobacillus-Streptococcus group
(Lab158) and Enterobacteria (Enter1432) were under the
detection limit. Total bacteria were detected with the
EUB338 probe. Details about the here used probes and
primer sequences are given in the additional file 1, Table
S1. The selected oligonucleotide probes target major bac-
terial population groups. Roseburia, E. rectale and Faecali-
bacterium groups are major butyrate producers, while
E. rectale, Roseburia, Bacteroides-Prevotella and Bifidobac-
terium respond to the supply of peptides [24-26].
Intestinal Roseburia decreases significantly in human sub-
jects on a low carbohydrate diet [27].
Measurement of in vitro fermentation of the cereal fiber
extract as used in the HCF and MIX diets
Fecal samples were collected from a healthy volunteer (age
25) who had no previous history of gastrointestinal disor-
ders and had not undergone antibiotic therapy within the
last six months. A fresh fecal sample was diluted ten-fold
(w/v) in pre-reduced phosphate-buffered saline (PBS)
(contents per liter: 8.5 g of NaCl, 0.3 g of KH2PO4,0 . 6go f
Na2HPO4, 0.1 g of peptone, 0.25 g of cysteine) and centri-
fuged (1 min, 300× g) to remove non-bacterial particles.
Before inoculation, the fecal bacteria were washed three
times with pre-reduced PBS (5 min, 8000× g). Ten-fold
diluted bacterial suspension was transferred to the fermen-
tation vessels (0.2% inoculum). Fermentations were carried
out in 250 ml glass vessels containing 125 ml bicarbonate
buffered medium (BIC) [contents per liter: 0.35 g of
K2HPO4,0 . 2 3go fK H 2PO4,0 . 5go fN H 4Cl, 2.25 g
of NaCl, 0.5 g of MgSO4*7H20, 0.07 g of CaCl2*2 H2O,
0.005 g of FeSO4*7H2O, 0.00015 g of NaSeO3,3 . 5m go f
tryptically digested peptone from casein, 3.5 mg of yeast
extract, 0.5 g of cysteine*HCl, 4.0 g of NaHCO3 and 3 ml
of trace element solution SL10 [28]. Medium (125 ml) was
added to 0.25 g of glucose or the cereal fiber extract
(HF101). The pH was adjusted to 7.5, the medium was
gassed with N2/CO2 (80:20 v/v) and autoclaved at 121°C
for 15 min. Following autoclaving five-fold concentrated
vitamin solution (4 ml/100 ml) was added [29]. Aliquots
were taken after 0, 24 and 46 h of incubation and ana-
lyzed. The pH was measured directly in the samples by
using a MultiCal pH-meter (WTW, Weilheim, Germany).
Measurements of optical density (OD) and in vitro
production of short-chain fatty acids (SCFA) were per-
formed as follows: One ml batch culture was centrifuged
(5 min, 14000 × g), the pellet was re-suspended in PBS
(1 ml) and the resulting OD was determined at 600 nm
(DU-640 spectrophotometer, Beckman Instruments Inc.,
Fullerton, CA). Gas chromatography (GC) of SCFA was
performed as described above.
Measurement of short chain fatty acids (SCFA) in fecal
samples
Fresh feces (300 mg) were diluted 5-fold in water and
centrifuged at 15000 × g for 5 min. Isobutyric acid (23.6
μl 12 mM, internal standard), 280 μl 0.36 M HClO4,a n d
270 μl 1 M NaOH were added to 200 μl of the superna-
tant. The mixture was lyophilized, and the residue was
re-dissolved in a mixture of 400 μl acetone and 100 μl
5 M formic acid. After centrifugation at 14,000 × g for
5 min at room temperature, 1 μl of the supernatant was
injected into the gas chromatograph. Authentic standards
were incorporated in all runs.
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(C5) and isovalerate (iso-C5) were measured with an HP
5890 series II gas chromatograph (Hewlett-Packard, Wald-
bronn, Germany) equipped with a HP-20 M (Carbowax
20 M) column (30 m × 0.53 mm; film thickness 0,3 μm)
and a flame ionization detector. Helium was used as car-
rier gas at a flow rate of 1 ml/min. The initial column tem-
perature of 75°C for 1 min was subsequently increased at a
rate of 20°C/min to 100°C and then to 150°C at a rate of
5°C/min. The final temperature of 150°C was maintained
for 3 min. The temperature of the injector and of the
detector was 200°C. The split ratio was 1:10.
Blood tests
Routine laboratory markers were measured by using
standard methods in the research laboratories of the Ger-
man Institute of Human Nutrition. Glucose concentra-
tions were measured in venous blood (ABX Pentra 400;
ABX Diagnostics, Montpellier, France), and additionally,
for the clamp studies, in arterialized blood samples.
Arterialized plasma glucose concentrations were mea-
s u r e di m m e d i a t e l yb yu s i n gt h eg l u c o s eo x i d a s em e t h o d
(Super-GL glucose analyzer; Dr. Müller, Freital,
Germany). Plasma plasminogen activator inhibitor-1 was
measured by using an enzyme-linked immunosorbent
assay (IBL, Hamburg, Germany; intra-assay CV: 4.7%;
inter-assay CV: 5%). Serum interleukin-10 (IL-10) was
measured by using a highly sensitive immune assay
(Quantikine, Wiesbaden, Germany; intra-assay CV: 6.6%;
inter-assay CV: 8.1%). C-reactive protein was measured
by using turbidimetric immunoprecipitation on an ABX
Pentra 400 (ABX Diagnostics; intra-assay CV: 1.6%;
inter-assay CV: 4.3%). Ghrelin was measured using an
enzyme immunometric assay (SPIbio, Montigny de
Bretonneux, France; intra-assay CV: 7.5%; inter-assay CV:
8.2%).
Euglycaemic hyperinsulinaemic clamps
Euglycaemic hyperinsulinaemic clamps were performed
as detailed previously [12].
Power calculation
This study was powered to detect diet-induced differ-
ences in whole-body insulin sensitivity between the HCF
and the HP groups [12]. Assuming a dropout rate of 30%
we required 26 participants for each treatment. However,
the sample size of the here investigated subset of partici-
pants who provided sufficient fecal samples on all study
days was adequate to show significant diet-induced dif-
ferences between groups on whole-body insulin sensitiv-
ity, both in the full model and in Bonferroni corrected
sub-analyses. Therefore, it was reasonable to assume that
sample size was sufficient for the detection of factors that
may contribute explaining the here observed changes of
whole-body insulin sensitivity.
Statistical analyses
Results are presented as mean ± SEM. Analyses of this
proof of principle nutritional intervention were per-
formed according to the study protocol (ClinicalTrials.
gov number, NCT00579657), in an attempt to exclude
confounding factors with known effects on the main
outcome measure (insulin sensitivity) that are likely to
obscure diet-induced effects. Participants who reported
that they were not able or willing to adhere to their
respective diets were also excluded. Details of all inclu-
sion and exclusion criteria have been published [12].
Eighty-four of the participants (controls, n = 22, HCF, n
= 18; HP, n = 22; and MIX, n = 22) completed the dietary
intervention successfully [12]. Of those 69 subjects pro-
vided sufficient fecal samples on all study days (controls, n
= 18, HCF, n = 16; HP, n = 19; and MIX, n = 16, Table 1).
All here presented analyses were performed in all partici-
pants. Diet-induced changes in whole-body insulin sensi-
tivity were re-calculated in this subset and analysed using
a mixed-model analysis for repeated measures, including
the 4 dietary treatments and 3 time points (weeks 0, 6,
and18) into one model. For separate investigation of diet-
ary effects at weeks 0, 6 and 18, respectively, one-factor
analysis of variance (ANOVA) with Bonferroni adjustment
for post hoc comparisons was performed. Not normally
distributed data were analysed using Kruskal-Wallis test
with Mann-Whitney U-tests for comparisons in sub-
groups. In order to detect potentially present smaller dif-
ferences in markers of colonic fermentation and dominant
groups of the gut microbiota between dietary intervention
groups, we additionally performed uncorrected subgroup
analyses for these parameters even if there was no signifi-
cant effect in the full model. Longitudinal changes within
groups were addressed by two-tailed Students’ T-test for
paired samples. p < 0.05 was considered significant.
Analyses were performed using SPSS version 16 (Chicago,
Illinois, USA).
Results
Dietary effects on dominant groups of the gut microbiota
Fecal samples collected after 0, 6 and 18 weeks of dietary
intervention were analyzed in duplicate for diet-induced
changes of dominant groups of the gut microbiota using
FISH coupled with flow cytometry. The distribution of
the targeted gut microbial groups was comparable
between the participants at baseline (Table 1). In the full
model there were no significant diet-induced changes in
any of the here investigated dominant groups of the
human gut microbiome, p > 0.23 for all measured gut
microbiota groups after 6 weeks, and p > 0.58 for all
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induced significant differences between groups after nor-
malisation for the baseline (p > 0.17 for all measured gut
microbiota groups after 6 weeks; and p > 0.18 for all
groups after 18 weeks).
Although no significant effects of the four diets were
detected in the full model, we additionally performed
subgroup analyses in order to detect potentially present
smaller differences between dietary groups. Again, no sig-
nificant differences were detected between groups both
after 6 and 18 weeks. Roseburia tended to be increased in
the HCF as compared to the HP group after 6 weeks of
dietary intervention (12.6 ± 2.5 vs 6.5 ± 1.3%, p = 0.068),
but not after 18 weeks (p = 0.37). No further trends were
observed between dietary groups (p > 0.19 for all other
measured gut microbiota groups). Re-analysing all the
microbiota data after normalizing for baseline value levels
(week 0) again did not show any significant diet-induced
effects.
When investigating longitudinal diet-induced changes
within groups, the following changes were detected:
controls, no significant changes (p > 0.21 for all gut
Table 1 Baseline characteristics of the participants
Characteristics of participants Control HCF HP MIX p value
1
Gender (males/females) 8/10 5/11 7/12 6/10 0.93
Age - yr 55.3 ± 1.9 54.2 ± 3.2 57.4 ± 1.8 55.3 ± 1.9 0.76
Waist circumference - cm 101.6 ± 2.1 101.4 ± 1.9 101.4 ± 2.6 100.6 ± 3.3 0.99
BMI (kg/m
2) 31.0 ± 0.8 31.9 ± 0.8 31.4 ± 0.9 31.4 ± 1.0 0.92
M-value (mg·kg
-1·min
-1) 4.4 ± 0.5 3.8 ± 0.4 4.0 ± 0.4 4.4 ± 0.4 0.67
Fecal SCFA (mM)
Acetate (C2) 40.2 ± 3.1 38.8 ± 4.5 39.3 ± 4.4 39.8 ± 3.9 0.88
Propionate (C3) 12.4 ± 1.1 13.3 ± 1.4 13.0 ± 1.3 15.1 ± 1.5 0.64
Butyrate (C4) 12.3 ± 1.5 12.8 ± 2.4 13.6 ± 1.9 13.1 ± 1.7 0.98
Valerate (C5) 2.3 ± 0.3 2.0 ± 0.3 2.2 ± 0.2 2.2 ± 0.2 0.66
Sum SCFA
1
Gut microbiota groups (%)
70.8 ± 5.3 69.5 ± 7.8 71.6 ± 6.7 73.1 ± 6.5 0.90
Bac303 7.1 ± 1.8 5.4 ± 1.4 5.5 ± 1.9 9.4 ± 3.0 0.72
Erec482 26.1 ± 2.7 24.3 ± 3.4 23.2 ± 2.9 23.0 ± 2.7 0.76
Rrec584 10.0 ± 2.2 10.6 ± 2.4 8.6 ± 1.8 6.9 ± 1.4 0.78
Clep866 11.4 ± 1.2 13.6 ± 1.7 14.1 ± 2.0 10.7 ± 1.7 0.66
Ato291 2.4 ± 0.6 2.8 ± 1.0 3.5 ± 0.7 3.8 ± 0.7 0.25
Bif164 4.0 ± 1.0 2.2 ± 0.8 2.7 ± 0.7 2.7 ± 1.0 0.46
Prop853 4.9 ± 1.2 7.9 ± 1.3 9.5 ± 1.8 6.7 ± 1.6 0.13
Fecal dry mass (%) 26.0 ± 1.8 28.2 ± 2.7 26.3 ± 1.8 26.4 ± 1.8 0.98
All values are mean ± SEM. HCF, diet high in cereal fiber; HP, diet high in protein; MIX, diet moderately high in both cereal and protein. M value, insulin
mediated glucose uptake as a measurement for whole body insulin sensitivity. SCFA, fecal short chain fatty acids.
Bac303, Bacteroides-Prevotella; Erec482, Clostridium coccoides - Eubacterium rectale cluster; Rrec584, Roseburia genus, Clep866, Clostridium leptum cluster; Ato291,
Atopobium cluster; Bif164, Bifidobacterium group; Prop853, clostridial cluster IX. Total bacteria were detected with the EUB338 probe.
1 P values refer to the respective treatment × time interaction in the full model
2Sum SCFA includes the measurement of fecal iso-acids
Table 2 Dominant groups of the gut microbiota, according to diet, after 6 and 18 weeks
6 weeks 18 weeks
control HCF HP MIX p value control HCF HP MIX p value
1
Bac303 (%) 9.9 ± 3.2 6.4 ± 1.7 5.4 ± 1.7 7.2 ± 1.5 0.65 7.1 ± 1.6 8.0 ± 2.0 7.9 ± 1.9 7.4 ± 2.4 0.88
Erec482 (%) 24.2 ± 3.2 27.9 ± 3.9 21.4 ± 3.1 25.2 ± 2.6 0.53 23.2 ± 2.5 24.2 ± 3.2 22.7 ± 1.6 23.5 ± 3.1 0.99
Rrec584 (%) 9.7 ± 1.9 12.6 ± 2.5 6.5 ± 1.3 8.0 ± 1.5 0.23 7.6 ± 1.5 8.2 ± 1.8 6.0 ± 1.2 8.4 ± 2.2 0.86
Clep866(%) 11.4 ± 1.4 12.5 ± 1.6 13.2 ± 1.4 12.3 ± 1.7 0.64 12.3 ± 1.5 14.5 ± 1.5 15.4 ± 1.7 13.2 ± 1.5 0.58
Ato291 (%) 2.9 ± 0.7 3.8 ± 1.1 5.2 ± 1.1 4.6 ± 1.0 0.25 3.2 ± 0.6 3.8 ± 0.7 4.9 ± 0.9 3.9 ± 0.4 0.67
Bif164 (%) 4.6 ± 1.1 4.0 ± 1.1 2.3 ± 0.8 2.1 ± 0.5 0.27 3.0 ± 0.9 2.9 ± 0.8 2.7 ± 0.8 2.8 ± 0.6 0.92
Prop853 (%) 5.3 ± 1.2 6.9 ± 1.6 6.2 ± 1.0 5.7 ± 1.2 0.83 5.9 ± 1.1 7.0 ± 1.9 6.7 ± 1.5 5.3 ± 1.3 0.94
All values are mean ± SEM. Baseline values are shown in Table 1. HCF, diet high in cereal fiber; HP, diet high in protein; MIX, diet moderately high in both cereal
and protein.
1P values refer to the respective treatment × time interaction in the full model. Bac303, Bacteroides-Prevotella; Erec482, Clostridium coccoides -
Eubacterium rectale cluster; Rrec584, Roseburia genus, Clep866, Clostridium leptum cluster; Ato291, Atopobium cluster; Bif164, Bifidobacterium group; Prop853,
clostridial cluster IX. Total bacteria were detected with the EUB338 probe.
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weeks; Bifidobacterium tended to decrease between
week 6 and week 18 (p = 0.079); HF, no significant
changes (p > 0.17 for all gut microbiota groups after 6
weeks; p > 0.15 for all groups after 18 weeks); HP:
Members of clostridial cluster IX decreased after 6-
weeks of HP diet (p = 0.017), but there was no signifi-
cant change between week 0 and week 18 (p = 0.11;
Table 2). Atopobium tended to increase after 6 weeks in
the HP group (p = 0.095) and was significantly increased
versus the baseline after 18 weeks (p = 0.024, Table 2).
No longitudinal changes in gut microbiota groups were
observed with the MIX diet.
In vitro fermentation of the cereal fiber extract
The here used cereal fiber extract contained mainly cel-
lulose (70%) and hemicelluloses (30%), as described in
detail [12,20]. There was no relevant in vitro fermenta-
tion of the cereal fiber extract after incubation for 24 h
and 46 h, whereas glucose solution that was used as
control was strongly fermented (Figure 1).
Diet induced changes in fecal SCFA profiles
Diet-induced effects on SCFA profiles were investigated
in fecal samples after 0, 6, and 18 weeks of dietary
intervention. Analyses for SCFA were performed in
duplicates. Baseline levels (week 0) of fecal SCFA
showed no significant differences between groups
(Table 1). Apart from a significant effect in the full
model for valeric acid (p = 0.037) which was driven
mainly by a significant increase of this SCFA in the HP
group after 6 weeks [week 0 (baseline) vs week 6, p =
0.002; week 0 vs week 18, p = 0.056, see Tables 1 and
3] and comparable to the increase seen with isovaleric
acid that was used as a biomarker for protein intake
[12], there were no diet-induced differences between
groups in other SCFA (p > 0.28 for all parameters,
Table 3). Subgroup analyses for valeric acid showed
significant differences after 6 weeks of dietary interven-
tion both between HP as compared with control (p =
0.028), and between HP as compared with HCF (p =
0.01; Table 3).
Re-analysing all the here investigated markers after
normalizing for baseline value levels (week 0) again did
not show any significant diet induced effects on fecal
SCFA. In addition, diet-induced effects on fecal valeric
acid concentrations failed to reach significance level in
the full model after correction for baseline levels (6
weeks, p = 0.076; 18 weeks, p = 0.90).
Diet induced differences within groups when compar-
ing data longitudinally (week 0 vs week 6 and 18,
respectively) are shown in Table 3.
Breath hydrogen concentrations
Results from investigating hydrogen breath concentra-
tions as a further marker for colonic carbohydrate fer-
mentation have been published and were not different
between dietary groups in all analyses [12].
Figure 1 In vitro fermentation of the cereal fiber extract. The figure shows in vitro fermentation of glucose in comparison to the cereal fiber
extract as used in the dietary supplements in the high cereal fiber (HCF) and moderately high cereal fiber/protein (MIX) groups. BIC depicts the
bicarbonate buffered medium used for solution of both glucose and the cereal fiber extract. SCFA, short chain fatty acids.
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In agreement with unchanged fecal SCFA profiles with
the HCF diet there were no significant changes in com-
monly proposed factors that have been shown to be
influenced by SCFA [1,16,30], which included circulating
levels of the orexigenic gut hormone ghrelin (full model,
6-weeks, p = 0.81, 18-weeks p = 0.85), and markers of
inflammation (hsCRP, 6-weeks, p = 0.33, 18-weeks p =
0.41; PAI-1, 6-weeks, p = 0.50, 18-weeks p = 0.61; and
IL-10, 6-weeks, p = 0.46, 18-weeks p = 0.46).
Diet-induced effects on fecal dry mass
Fecal dry mass significantly increased in the HCF group
between 0 and 6 weeks (p = 0.009), but was comparable to
baseline after 18 weeks (p = 0.56) (Table 3). Fecal dry
mass also tended to increase in the MIX group after 18
weeks (p = 0.092), but not after 6 weeks (p = 0.22) of diet-
ary intervention (Table 3). There were no diet-induced
effects on fecal dry mass in the control (6 weeks, p = 0.71;
18 weeks, p = 0.35) and in the HP groups (6 weeks, p =
0.24; 18 weeks, p = 0.7) (Table 3).
Diet-induced effects on whole-body insulin sensitivity
Results of diet-induced effects on whole-body insulin sen-
sitivity in the entire study group have been published [12].
We here present results from sub-group analyses, includ-
ing all participants that were not excluded according to
the study protocol and provided sufficient fecal samples
on all study days (n = 69). The isoenergetic dietary inter-
vention significantly influenced whole-body insulin sensi-
tivity (mixed-model analysis for repeated measures,
treatment × time interaction, 0-18 weeks: p = 0.046; abso-
lute values: M-value 3.8 ± 0.4 (week-0) vs 4.3 ± 0.4 mg·kg
-
1·min
-1 (week-6), p = 0.015; and M-value 3.8 ± 0.4 (week-
0) vs 4.5 ± 0.6 mg·kg
-1·min
-1 (week-18), p = 0.065). Diet
induced effects on insulin sensitivity expressed as percen-
tage of the baseline value after 6 and 18 weeks were com-
parable to the results in the entire study group (ANOVA,
week-6, p = 0.034; week-18, p = 0.27). Therefore the
subgroup described here showed similar changes in insulin
sensitivity as the entire study group [12].
Further outcomes
Effects of the here investigated isoenergetic diets on
body fat distribution and liver fat content have been
published and showed no differences between groups
[8].
Discussion
Colonic fermentation of undigested dietary fibers with
the production of SCFA has been proposed as one of the
potential mechanisms that may explain improved insulin
sensitivity and reduced diabetes risk in subjects consum-
ing high fiber diets including diets high in cereal fibers
[1,3,4,31,32].
We here show that implementation over a period of 18
weeks of a supplemented diet high in cereal fibers (> 40
g/day) markedly and significantly improved whole-body
insulin sensitivity in the full model, but no differences
between dietary groups in various markers of colonic car-
bohydrate fermentation including fecal SCFA, breath
hydrogen concentrations [8], and several of their pro-
posed targets were detected. In subgroup analyses, the
only detected diet-induced effect was an increase of fecal
valerate concentrations in the HP group which was
expected in agreement with the also observed increase in
fecal isovalerate [12] that has been proposed as a biomar-
ker for dietary protein intake [33].
We further investigated diet-induced effects on dominant
groups of the gut microbiota that are known to be involved
in carbohydrate fermentation and again found no signifi-
cant changes in the here investigated microbiota groups.
Roseburia tended to increase in the HCF and to decrease
in the HP group which was in agreement with a previous
study showing decreased Roseburia with a lower carbohy-
drate intake [27]. The dietary supplements of the HCF and
M I Xg r o u p sa l s os h o w e dn oin vitro fermentation, and
changes in hydrogen breath tests were comparable between
Table 3 Markers of colonic fermentation, according to diet, after 6 and 18 weeks
6 weeks 18 weeks
control HCF HP MIX p value control HCF HP MIX p value
1
Fecal SCFA (mM)
Acetate (C2) 34.4 ± 3.3 42.2 ± 6.1 37.4 ± 2.8 41.7 ± 5.4 0.75 37.2 ± 2.6 44.1 ± 5.7 40.4 ± 3.9 39.8 ± 5.3 0.79
Propionate (C3) 12.8 ± 1.8 13.1 ± 1.7 15.0 ± 1.6 15.4 ± 1.6 0.28 14.1 ± 1.4 16.5 ± 2.2 17.4 ± 2.3 13.7 ± 1.2 0.77
Butyrate (C4) 11.3 ± 2.1 15.1 ± 2.8 15.6 ± 1.7 14.8 ± 2.7 0.41 13.3 ± 1.8 13.8 ± 2.0 12.9 ± 1.4 12.4 ± 1.7 0.98
Valerate (C5) 2.2 ± 0.3 1.9 ± 0.3 3.1 ± 0.3 2.4 ± 0.3 0.037 2.9 ± 0.3 2.4 ± 0.3 3.1 ± 0.4 2.6 ± 0.3 0.48
Sum SCFA
2 63.7 ± 6.4 74.8 ± 9.5 75.6 ± 5.9 77.6 ± 9.0 0.42 71.6 ± 5.6 80.4 ± 9.7 78.2 ± 7.2 72.1 ± 7.3 0.90
Fecal dry mass (FDM, %)
FDM (%) 25.4 ± 2.1 34.3 ± 2.7 28.2 ± 1.9 28.3 ± 1.8 0.08 27.8 ± 1.4 30.4 ± 2.7 27.0 ± 1.7 30.1 ± 2.3 0.35
All values are mean ± SEM. Baseline values are shown in Table 1. HCF, diet high in cereal fiber; HP, diet high in protein; MIX, diet moderately high in both cereal
and protein.
1P values refer to the respective treatment × time interaction in the full model.
2Sum SCFA includes the measurement of fecal iso-acids
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including the control diet were based on plant rich foods.
Therefore, the HCF diet-induced effects on whole-body
insulin sensitivity were not matched by changes in mar-
kers of colonic fermentation and/or the composition of
the gut microbiota, neither in the full model nor in addi-
tionally performed uncorrected subgroup analyses, and
there was also no tendency to more pronounced effects
after 18 versus 6 weeks of dietary intervention. The magni-
tude of improvement of insulin sensitivity with the HCF
diet was comparable to results obtained from previous
short-term (24 hours and 72 hours) randomized con-
trolled cross-over studies from our laboratory, using the
same cereal fiber extract [11,20], and independent from
the ability of various insoluble fibers to change markers of
colonic fermentation [20]. Furthermore, effects of cereal
fiber intake on markers of glucose metabolism have been
shown as short as 75 min after its intake, an interval that
is likely too short to induce relevant changes on the gut
microbiota [2]. In the few available long term studies in
rodents that investigated otherwise comparable high fiber
diets differing in their fermentation rate the short term
beneficial effects of highly fermentable dietary fibers were
abolished after prolonged intake, resulting in increased
body weight and higher insulin resistance [34,35]. This
was likely explained by a contribution of higher SCFA pro-
duction to total energy intake [34], an effect that has been
suggested to be relevant also in humans [36]. Most impor-
tantly, data from large prospective cohort studies consis-
tently indicate that a high cereal fiber intake reduces
diabetes risk as much as 30%, whereas more readily fer-
mentable sorts of dietary fibers from fruit and vegetables
show inconclusive results on this outcome [7,8,37]. We
therefore suggest that improved insulin sensitivity with
cereal fibers may not depend on the concept of colonic
carbohydrate fermentation.
Strengths of our study included the state-of-the-art mea-
surement of insulin sensitivity, the provision of isoener-
getic diets, the provision of supplements to enhance
discrimination between diets, and the use of biomarkers to
assess compliance [12]. Limitations were: an 18-weeks
intervention might have been too short to detect changes
in the gut microbiota and/or fecal SCFA [1], and other
here not measured factors (such as bile acids [38]) might
have been influenced by the HCF diet. Furthermore, when
FISH is used only selected bacterial groups are targeted
depending on the selected probes. With a probe set cover-
ing essentially the same bacterial groups, coverage of 80%
of the total human microbiota was shown previously [27];
however, complete coverage would require a non-targeted
16S rRNA gene-sequencing approach [39,40] that has not
been available in this study.
Finally, we investigated changes of SCFA in fecal sam-
ples and the fraction of SCFA that was potentially
absorbed by the host was not measured; analysis of
SCFA in portal blood samples would be desirable but is
not feasible in dietary intervention studies in humans,
whereas the measurement of SCFA in peripheral blood
faces various limitations, due to interference with endo-
genous production of acetate and butyrate by fat oxida-
tion, and changes in propionate due to amino acid
metabolism [1]. Since we did not observe any HCF
induced increase of SCFA at the anatomical site of pro-
duction (fecal samples from the colon), it is unlikely
that changes in peripheral (and/or portal) blood in the
HCF group would have been detected, and if so, these
were unlikely to be explained by HCF-induced increases
in colonic fermentation since colonic/fecal SCFA were
unchanged in this group.
Despite these limitations, the combination of results
including lack of in vitro fermentation of the cereal fiber
extract as used for preparation of the dietary supplements
in the HCF and MIX groups, no diet-induced changes in
breath hydrogen concentrations [12], no changes in the
composition of dominant groups of the gut microbiota,
and unchanged fecal SCFA concentrations including the
measurement of several of their proposed targets (serum
ghrelin, several inflammatory markers) did not support
the hypothesis that cereal fiber induced production of
SCFA was a key driver in the here observed rapid onset
improvement of whole-body insulin sensitivity with the
HCF diet.
Conclusions
Potential changes in SCFA and dominant groups of the
gut microbiota in longer-term interventions may further
contribute to beneficial effects of HCF diets. However,
our here provided data do not lend support to the
hypothesis that colonic carbohydrate fermentation with
the production of SCFA was one of the key mechanisms
mediating the observed rapid onset and significant
improvement of whole-body insulin sensitivity in over-
weight subjects consuming a supplemented HCF-diet.
Additional material
Additional file 1: Table S1: FISH analysis - probes. additional file 1
shows the probes used for the analysis of diet-induced changes in gut
microbiota composition.
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